

# Package ‘SAME’

January 20, 2025

**Type** Package

**Title** Seamless Adaptive Multi-Arm Multi-Stage Enrichment

**Version** 0.1.0

**Maintainer** Chengxue Zhong <czhong9106@gmail.com>

**Description** Design a Bayesian seamless multi-arm biomarker-enriched phase II/III design with the survival endpoint with allowing sample size re-estimation.

James M S Wason, Jean E Abraham, Richard D Baird, Ioannis Gournaris, Anne-Laure Val-  
lier, James D Brenton, Helena M Earl, Adrian P Mander (2015) <[doi:10.1038/bjc.2015.278](https://doi.org/10.1038/bjc.2015.278)>.

Guosheng Yin, Nan Chen, J. Jack Lee (2018) <[doi:10.1007/s12561-017-9199-7](https://doi.org/10.1007/s12561-017-9199-7)>.

Ying Yuan, Beibei Guo, Mark Munsell, Karen Lu, Amir Jazaeri (2016) <[doi:10.1002/sim.6971](https://doi.org/10.1002/sim.6971)>.

**License** GPL-2

**Encoding** UTF-8

**LazyData** true

**RoxygenNote** 7.2.1

**Imports** boot, rjags, coda, extraDistr, survival, ggplot2, expint

**Suggests** testthat, mockery, knitr, rmarkdown

**Depends** R (>= 3.3.0)

**NeedsCompilation** no

**Author** Chengxue Zhong [aut, cre],

Haitao Pan [aut],

Hongyu Miao [aut]

**Repository** CRAN

**Date/Publication** 2023-01-16 10:10:08 UTC

## Contents

conduct.phase2 . . . . .	2
conduct.phase3 . . . . .	3
example.1 . . . . .	3
example.2 . . . . .	4
find.cutoffs . . . . .	5

sim.trial . . . . .	6
sim.trial.2 . . . . .	7

<b>Index</b>	<b>9</b>
--------------	----------

---

conduct.phase2	<i>Function to identify the most promising treatment-biomarker-linked subgroup</i>
----------------	--

---

### Description

This function is used to estimate the effect size of each subgroup and to select the most promising subgroup.

### Usage

```
conduct.phase2(formula, surv, event, data)
```

### Arguments

formula	a formula object, with the combinations of treatment and biomarker term, e.g., formula = "T1:B1+T1:B2+T2:B1+T2:B2"
surv	survival time
event	the status indicator, 0=alive, 1=dead
data	a data.frame in which to interpret the variables named in the formula

### Value

conduct.phase2() select the most effective subgroup and returns the estimated hazard ratio.

### Examples

```
conduct.phase2(formula = "T1:B1+T1:B2+T2:B1+T2:B2", surv = "surv",
event = "death", data = "example.1")
```

---

conduct.phase3	<i>Function to estimate the hazard ratios and other statistics of the selected subgroup</i>
----------------	---

---

**Description**

This function is used to estimate the effect size of the selected subgroup.

**Usage**

```
conduct.phase3(data, eta, theta)
```

**Arguments**

data	a data.frame in which to interpret the variables named in the formula
eta	a cutoff probability for the strength of evidence for decision-making
theta	a clinically meaningful treatment effect size defined by clinicians

**Value**

```
conduct.phase3()
```

**Examples**

```
conduct.phase3(example.2, eta=0.8, theta=0.95)
```

---

example.1	<i>A Time-to-event dataset containing the time and other attributes of 643 patients.</i>
-----------	--

---

**Description**

A Time-to-event dataset containing the time and other attributes of 643 patients.

**Usage**

```
example.1
```

**Format**

A data frame with 643 rows and 6 variables:

**T1** binary variable, receive treatment 1=1, not receive treatment 1=0

**T2** binary variable, receive treatment 2=1, not receive treatment 2=0

**B1** binary variable, biomarker 1 positive=1, biomarker 1 negative=0

**B2** binary variable, biomarker 2 positive=1, biomarker 2 negative=0

**death** the status indicator, alive=0, dead=1

**surv** survival time or follow up time ...

---

example.2

*A Time-to-event dataset containing the time and other attributes of 643 patients.*

---

**Description**

A Time-to-event dataset containing the time and other attributes of 643 patients.

**Usage**

example.2

**Format**

A data frame with 643 rows and 6 variables:

**T1** binary variable, receive treatment 1=1, not receive treatment 1=0

**T2** binary variable, receive treatment 2=1, not receive treatment 2=0

**B1** binary variable, biomarker 1 positive=1, biomarker 1 negative=0

**B2** binary variable, biomarker 2 positive=1, biomarker 2 negative=0

**death** the status indicator, alive=0, dead=1

**surv** survival time or follow up time

**survtime** survival time or follow up time

**treatments** categorical variable, indicating treatments received ...

---

find.cutoffs	<i>Function to calibrate the cutoff points under null hypothesis</i>
--------------	--

---

**Description**

This function is used to calibrate the cutoff points under null hypothesis using a multi-arm multi-stage biomarker-enriched design with time-to-event endpoints.

**Usage**

```
find.cutoffs(
  median.c,
  K,
  L,
  lfu,
  alpha,
  power,
  accrate,
  theta,
  bio.preva,
  FAtime.phase3,
  N.iter
)
```

**Arguments**

median.c	The median survival time for control group
K	Number of biomarkers
L	Information fraction in terms of the accumulative events in phase II stage, e.g., $K = c(1/4, 1/2, 1)$
lfu	Follow-up time
alpha	One-sided familywise error rate
power	Power
accrate	Accrual rate
theta	A clinically meaningful treatment effect size defined by clinicians
bio.preva	Prevalence of biomarker(s)
FAtime.phase3	the study ending time of phase III
N.iter	Number of iterations

**Value**

find.cutoffs() returns the calibrated cutoff points that can control the type I error rate.

**Examples**

```
find.cutoffs(median.c=12,K=2,L=c(1/4,1/2,1),lfu=0,alpha=0.05,power=0.9,
             accrate=15,theta=log(1.25),bio.preva=c(0.4,0.6),FAtime.phase3=48,
             N.iter=3)
```

---

sim.trial	<i>Function to simulate Bayesian seamless multi-arm biomarker-enriched phase II/III designs</i>
-----------	---

---

**Description**

This function finds the required number of events using a multi-arm multi-stage biomarker-enriched design with time-to-event endpoints.

**Usage**

```
sim.trial(
  median.c,
  hr,
  K,
  L,
  lfu,
  alpha,
  power,
  accrate,
  theta,
  bio.preva,
  FAtime.phase3,
  N.iter
)
```

**Arguments**

median.c	The median survival time for control group
hr	Alternative hazard ratio
K	Number of biomarkers
L	Information fraction in terms of the accumulative events in phase II stage, e.g., $K = c(1/4, 1/2, 1)$
lfu	Follow-up time
alpha	One-sided familywise error rate
power	Power
accrate	Accrual rate
theta	A clinically meaningful treatment effect size defined by clinicians

bio.preva	Prevalence of biomarker(s)
FAtime.phase3	the study ending time of phase III
N.iter	Number of iterations

### Value

sim\_trial() returns the nominal type I error rate and calibrated cutoff points, nominal power under user-defined hypothesis, empirical power under user-defined number of simulations, the duration of trial(time), the number of events (num\_evs), the number of patients (num\_pts) from different stages. The function can also display the number of events and patients under the selected subgroup, the distribution of decision zones and the estimated hazard ratio for the final analysis.

### Examples

```
sim.trial(median.c=12,hr=c(1,1,1,0.6),K=2,L=c(1/4,1/2,1),lfu=0,
          alpha=0.05,power=0.9,accrate=15,theta=log(1.25),
          bio.preva=c(0.4,0.6),FAtime.phase3=48,N.iter=5)
```

---

sim.trial.2	<i>Function to simulate Bayesian seamless multi-arm biomarker-enriched phase II/III designs with user-defined cutoff points</i>
-------------	---

---

### Description

This function finds the required number of events using a multi-arm multi-stage biomarker-enriched design with time-to-event endpoints with the user-defined cutoff points.

### Usage

```
sim.trial.2(
  median.c,
  hr,
  K,
  L,
  lfu,
  alpha,
  power,
  accrate,
  theta,
  bio.preva,
  FAtime.phase3,
  eta,
  futility,
  superiority,
  N.iter
)
```

**Arguments**

median.c	The median survival time for control group
hr	Alternative hazard ratio
K	Number of biomarkers
L	Information fraction in terms of the accumulative events in phase II stage, e.g., $K = c(1/4, 1/2, 1)$
lfu	Follow-up time
alpha	One-sided family-wise error rate
power	Power
accrate	Accrual rate
theta	A clinically meaningful treatment effect size defined by clinicians
bio.preva	Prevalence of biomarker(s)
FAtime.phase3	the study ending time of phase III
eta	A cutoff probability for the strength of evidence for decision-making and defined by user.
futility	cutoff point for futility termination
superiority	cutoff point for superiority termination
N.iter	Number of iterations

**Value**

sim.trial.2() returns the nominal type I error rate, nominal power under user-defined hypothesis, empirical power under user-defined number of simulations, the duration of trial(time), the number of events (num\_ews), the number of patients (num\_pts) from different stages. The function can also display the number of events and patients under the selected subgroup, the distribution of decision zones and the estimated hazard ratio for the final analysis.

**Examples**

```
sim.trial.2(median.c=12,hr=c(1,1,1,0.6),K=2,L=c(1/4,1/2,1),lfu=0,alpha=0.05,
power=0.9,accrate=15,theta=log(1.25),bio.preva=c(0.4,0.6),
FAtime.phase3=48,eta=0.2,futility=0.1,superiority=0.9,
N.iter=3)
```



# Index

## \* datasets

example.1, 3

example.2, 4

conduct.phase2, 2

conduct.phase3, 3

example.1, 3

example.2, 4

find.cutoffs, 5

sim.trial, 6

sim.trial.2, 7